The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab in the second line setting for locally advanced unresectable, recurrent, and/or metastatic HCC cohort and to assess the efficacy and safety of RP2 in combination with durvalumab after chemotherapy is discontinued in the first line setting for unresectable locally advanced or metastatic BTC cohort.
A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/ or Metastatic Hepatocellular Carcinoma
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.